



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/866,458	05/25/2001	Gary G. Meadows	618.002US1	4123

21186 7590 10/10/2002

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
P.O. BOX 2938  
MINNEAPOLIS, MN 55402

[REDACTED] EXAMINER

GOLDBERG, JEROME D

ART UNIT	PAPER NUMBER
1614	9

DATE MAILED: 10/10/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>
	09/866,458	MEADOWS ET AL.
	<b>Examiner</b>	<b>Art Unit</b>
	Jerome D Goldberg	1614

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 28 June 2002.
- 2a) This action is **FINAL**.                    2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 1 and 4-34 is/are pending in the application.
- 4a) Of the above claim(s) 5-7 and 21-30 is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) 1, 4, 8-20 and 31-34 is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) The proposed drawing correction filed on \_\_\_\_\_ is: a) approved b) disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) The oath or declaration is objected to by the Examiner.

#### Priority under 35 U.S.C. §§ 119 and 120

- 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some \* c) None of:
1. Certified copies of the priority documents have been received.
  2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_ .
  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) The translation of the foreign language provisional application has been received.
- 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

#### Attachment(s)

- |  |  |
|--|--|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                               | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ . |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)           | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)  |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ . | 6) <input type="checkbox"/> Other: _____ .                                   |

Art Unit: 2913

Claims 5-7 and 21-30 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in Paper No. 5.

This application contains claims 5-7 and 21-30 drawn to an invention nonelected with traverse in Paper No. 5. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

Applicants are now required to cancel the non-elected claims and non-elected subject matter from the other claims. It noted that applicants only elected the compound fluoxetine for examination on the merits.

Claims 1, 4, 8-20 and 31-34 are still being examined as they read on the elected invention of treating cancers with fluoxetine.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was

Art Unit: 2913

not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1, 4, 8-20 and 31-34 are rejected under 35 U.S.C. 103(a) as being unpatentable over the Brandes patent of record for the reasons fully set forth in Paper No. 6, pages 2-3.

Applicants' remarks are noted. Applicant's state in Paper No. 8, page 4 lines 5-7 that "Brandes teaches that the intracellular histamine binding antagonists promote malignant cell proliferation ... and that fluoxetine increases the proliferation of tumor cells". This is noted but the patent claims are directed to employing a anticancer agent with the fluoxetine, which would read on applicants' method for treating cancer. Moreover, the instant claim 5 adds a chemotherapeutic agent to the method for treating cancer. Claims directed to "consisting of" in ~~use~~ <sup>use</sup> of "comprising" would overcome this rejection ~~are only directed to treating melanomas including metastatic melanomas and no other types of tumors or cancer are disclosed.~~

Claims 1, 8-14, 16-18, 31, 32 and 33 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for the specific tumors or cancers disclosed, does not reasonably provide enablement for the term "tumor" or "cancer". The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. The term "cancer" in claims 1, 8-14, 16-18 and 31 and "cancer" in claims 8-14, 16-18, 32 and 33 lacks clear exemplary support. Applicants'

Art Unit: 2913

remarks are noted but the showings of record are only directed to treating melanomas  
*are disclosed*  
including metastatic melanomas and no other types of tumors or cancer *of one type of*  
*Clearly, this*  
cancer would not support the broad ranges of carcinomas and sarcomas that effect  
mammals.

Claims 4 and 34 are rejected under 35 U.S.C. 112, second paragraph, as being  
indefinite for failing to particularly point out and distinctly claim the subject matter which  
applicant regards as the invention.

Claims 4 and 34 are improperly drawn to the same method. Correction is  
required.

Applicant's amendment necessitated the new ground(s) of rejection presented in  
this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP  
§ 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37  
CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE  
MONTHS from the mailing date of this action. In the event a first reply is filed within  
TWO MONTHS of the mailing date of this final action and the advisory action is not  
mailed until after the end of the THREE-MONTH shortened statutory period, then the  
shortened statutory period will expire on the date the advisory action is mailed, and any  
extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of  
the advisory action. In no event, however, will the statutory period for reply expire later  
than SIX MONTHS from the date of this final action.

Art Unit: 2913

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jerome Goldberg whose telephone number is (703) 308-4606. The examiner can normally be reached on Monday to Thursday from 9:00 AM to 3:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel can be reached on (703) 308-4725. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4556 for regular communications and (703) 305-3592 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.



Goldberg/LR  
October 4, 2002

JEROME D. GOLDBERG  
PRIMARY EXAMINER